Effects of Oxytocin on Reinforcement Learning and Interoception

NCT ID: NCT05245708

Last Updated: 2024-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-15
• Study Completion Date: 2021-12-15

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin has effects on reinforcement learning under dynamic environment and interoceptive processing based on behavioral and electroencephalogram (EEG) responses.

Detailed Description

A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. (1) Participants first complete a probabilistic reward learning task 45 minutes after treatment with behavioral (response time and accuracy) and EEG data (ERP components such as FRN, ERN and P300) being collected during this task. (2) A resting-state recording and a heartbeat counting task are conducted following the learning task with ECG and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), the Cognitive Flexibility Inventory(CFI), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the tasks.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

oxytocin

a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

Intranasal oxytocin

Intervention Type: DRUG

Each subject will be assigned to intranasal administration of oxytocin (24 IU).

placebo

a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

intranasal placebo

Intervention Type: DRUG

Each subject will be assigned to intranasal placebo.

Interventions

Intranasal oxytocin

Each subject will be assigned to intranasal administration of oxytocin (24 IU).

Intervention Type: DRUG

intranasal placebo

Each subject will be assigned to intranasal placebo.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy subjects without any past or present psychiatric or neurological disorders.

Exclusion Criteria

• History of brain injury medical or mental illness.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 28 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Shuxia Yao

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yao Shuxia, Dr

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China

Locations

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, China

Countries

China

Other Identifiers

UESTC-neuSCAN-83

Identifier Type: -

Identifier Source: org_study_id